Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for Kymera Therapeutics (KYMR) over the last 1 years, with Dec 2019 value amounting to $59.9 million.

  • Kymera Therapeutics' Preferred Stock Liabilities was N/A to $59.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $59.9 million, marking a year-over-year change of. This contributed to the annual value of $59.9 million for FY2019, which is N/A change from last year.
  • According to the latest figures from FY2019, Kymera Therapeutics' Preferred Stock Liabilities is $59.9 million.
  • In the past 5 years, Kymera Therapeutics' Preferred Stock Liabilities ranged from a high of $59.9 million in FY2019 and a low of $59.9 million during FY2019.
  • For the 1-year period, Kymera Therapeutics' Preferred Stock Liabilities averaged around $59.9 million, with its median value being $59.9 million (2019).